Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
Astellas Pharma ( OTCPK:ALPMF ) unit Audentes Therapeutics reports the third death in its Phase 1/2 ASPIRO study evaluating gene therapy AT132 in patients with X-linked myotubular myopathy , a rare serious and life-threatening inherited disorder characterized by weakness in the skeletal...
Original post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Astellas Pharma Inc (ALPMF) Q1 2021 Earnings Conference Call August 04, 2020 3:00 AM ET Company Participants Naoki Okamura – Representative Director and Executive Vice President Mike Kitagawa – Senior Vice President of Development Project Management Yukio Matsui ...
The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q1 earnings Read more ...
Astellas Pharma ( OTCPK:ALPMF ) : Q1 GAAP EPS of ¥27.12. More news on: Astellas Pharma Inc., Astellas Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...
Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...
Kiniksa Reports Positive Outcome from 28-Day Clinical Trial Kiniksa Pharmaceuticals Ltd. ( KNSA ) announced that it has received positive data from its COVID-19 treatment trial. This 28 day clinical outcomes data pertains to the open label treatment protocol with mavrilimumab. The compan...
Astellas Pharma ( OTCPK:ALPMF ) announces positive results from a Phase 3 clinical trial, DOLOMITES , evaluating roxadustat for the treatment of anemia in non-dialysis-dependent adults with stage 3-5 chronic kidney disease. The data were virtually presented at the European Renal Associati...
Japan's Ministry of Health, Labor and Welfare approves Astellas Pharma's ( OTCPK:ALPMF ) Xtandi (enzalutamide) for the treatment of prostate cancer patients with distant metastases. More news on: Astellas Pharma Inc., Pfizer Inc., Astellas Pharma Inc., Healthcare stocks news, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...